Tirzepatide 15 mg vial (GLP1+GIP)

Thirzepatide 15mg - chemical structure and molecular characterization

Tirzepatide 15mg is a synthetic peptide designed as a dual GLP-1R and GIPR receptor agonist. The molecule consists of a modified amino acid sequence linked to a lipid chain that allows reversible binding to albumin.

The use of structural modifications (including amino acid substitutions to increase resistance to enzymatic degradation and acylation) prolongs half-life and metabolic stability in the biological environment.

The molecular weight of tirzepatydu is about 4813 Da, which classifies it as a high-molecular-weight complex peptide, typical of new-generation incretin analogs.

Structural studies indicate that the molecule's conformation allows selective binding to the transmembrane domains of GLP-1R and GIPR receptors, leading to activation of intracellular Gs protein-dependent signaling and an increase in cAMP.

Thirzepatide 15mg as a laboratory reagent

In the research community, tirzepatide 15mg is used as a reference material in projects on:

• Incretin receptor pharmacology,

• GPCR signaling,

• Regulation of glucose and lipid metabolism,

• Integration of appetite and energy balance control mechanisms.

Dual receptor activation allows us to analyze the synergistic effects of the GIP/GLP-1 axis in cellular and preclinical models.

In vitro studies have shown that activation of these receptors leads to an increase in cAMP, modulation of gene expression related to glucose metabolism, and effects on mitochondrial activity.

Tirzepatide 15mg in clinical trials

The 15 mg dose was the highest weekly dose analyzed in phase III clinical programs.

In the study SURMOUNT-1 published in New England Journal of Medicine (2022) reported:

• Average weight reduction of ~20.9% after 72 weeks,

• ≥20% weight reduction in more than 50% participants,

• Improving lipid and glycemic parameters.

In the program SURPASS-2 showed a significant reduction in HbA1c compared to the Semaglutide.

The safety profile was dose-dependent, and the most commonly reported side effects were gastrointestinal.

Significance in preclinical models

In preclinical studies, tirzepatide 15 mg provides a model for analysis:

• Dose-response relationship at maximum receptor activation,

• integrating incretin signaling,

• The effects of GIPR and GLP-1R activation on tissue metabolism.

In animal models, changes in the expression of genes related to lipid metabolism and regulation of carbohydrate metabolism have been observed, which is interpreted as an effect of integrated hormonal modulation.

Nature of the product

Tirzepatide 15 mg offered in the laboratory market is a reference material intended for research and analytical use only (Research Use Only). It is not intended for therapeutic use outside of controlled clinical trials.

Scientific sources:

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity.
   New England Journal of Medicine, 2022.
   https://pubmed.ncbi.nlm.nih.gov/35658024/

2. Frías JP et al. Thirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
   New England Journal of Medicine, 2021.
   https://pubmed.ncbi.nlm.nih.gov/34170647/

3. Min T. et al. Mechanisms of dual GIP/GLP-1 receptor agonism.
   https://pmc.ncbi.nlm.nih.gov/articles/PMC10107501/

Product intended for scientific research and laboratory analysis. All articles and information on this site are for informational and educational purposes only.